Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis (Bristol-Myers Squibb Company)

(Source: Bristol-Myers Squibb Company) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today the commercial launch of the ORENCIA ClickJect Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis (RA). The ORENCIA ClickJect delivers 125 mg of subcutaneous (SC) ORENCIA with push button operation and injection confirmation, which may reduce the possibility of user errors. The ORENCIA ClickJect has an ergonomic design and non-slip grip that may allow for control by dexterity-compromised patients.ORENCIA is the only RA biologic that offers three administration options: IV infusion, prefilled syringe and...